Interleukin-6 and soluble interleukin-6 receptor suppress osteoclastic differentiation by inducing PGE$_2$ production in chondrocytes

Kazuhiro Honda

Division of Applied Oral Sciences, Nihon University Graduate School of Dentistry, Tokyo, Japan

(Received 24 December 2010 and accepted 5 February 2011)

Abstract: This study examined how interleukin-6 (IL-6) and soluble IL-6 receptor (sIL-6r) influence osteoclastic differentiation through the function of chondrocytes. Chondrocytes were cultured with or without IL-6 and/or sIL-6r in the presence or absence of NS398, a specific inhibitor of cyclooxygenase (COX)-2, for up to 28 days. Chondrocytes were also cultured with or without IL-6 and sIL-6r for 28 days, and the conditioned medium from cells cultured without IL-6 and sIL-6r was used to induce differentiation of RAW264.7 cells into osteoclast precursors. Osteoclastic differentiation was assessed by tartrate-resistant acid phosphatase (TRAP) staining. Expression of osteoprotegerin (OPG), receptor activator of NF-$\kappa$B ligand (RANKL), COX-2, and prostaglandin E$_2$ (PGE$_2$) increased in cells exposed to IL-6 and sIL-6r, whereas expression of macrophage colony-stimulating factor (M-CSF) and bone resorption-related enzymes decreased. NS398 blocked the stimulatory/suppressive effects of IL-6 and sIL-6r on the expression of OPG, RANKL, and M-CSF. Fewer TRAP-positive multinucleated cells were detected after treatment with conditioned medium from IL-6- and sIL-6r-treated chondrocytes than after treatment with conditioned medium from untreated chondrocytes. These results suggest that IL-6 and sIL-6r interfere with osteoclast function through the involvement of chondrocytes. Specifically, they appear to suppress the differentiation of osteoclast precursors into osteoclasts by inducing chondrocytic PGE$_2$ production, which, in turn, increases OPG secretion and decreases M-CSF secretion by chondrocytes. (J Oral Sci 53, 87-96, 2011)

Keywords: interleukin-6; chondrocytes; osteoclast precursors; osteoprotegerin; prostaglandin E$_2$.

Introduction

Inflammation-mediated bone loss is a major feature of various bone diseases, including chronic periodontitis, rheumatoid arthritis, and osteoarthritis. It is caused by an imbalance in bone remodeling that favors resorption. This imbalance results from increases in the levels of cytokines and mediators, such as interleukin (IL)-1, IL-6, tumor necrosis factor-$\alpha$, and prostaglandin E$_2$ (PGE$_2$), in inflammatory tissues (1).

IL-6 contributes to the development of arthritis and is present at high concentrations in the serum and synovial fluid of patients with chronic rheumatoid arthritis and temporomandibular joint (TMJ) osteoarthritis (2-4). Soluble IL-6 receptor (sIL-6r) is also elevated in the serum and synovial fluid of rheumatoid arthritis patients (5,6). Elevated concentrations of IL-6 and sIL-6r in the serum and synovial fluid of patients with arthritis have been implicated in the severe joint tissue destruction that characterizes this group of conditions (7). Additionally, IL-6 is closely associated with the expression of receptor activator of NF-$\kappa$B (RANK) ligand (RANKL) and osteoprotegerin (OPG) in osteoblasts (8).

RANKL, macrophage colony-stimulating factor (M-CSF), and OPG are key regulators of osteoclastogenesis.

Correspondence to Dr. Kazuhiro Honda, Department of Fixed Prosthodontics, Nihon University School of Dentistry, 1-8-13 Kanda-Surugadai, Chiyoda-ku, Tokyo 101-8310, Japan
Tel: +81-3-3219-8145
Fax: +81-3-3219-8351
E-mail: honda@dent.nihon-u.ac.jp
(9-12). RANKL is highly expressed on osteoblasts/stroma cells and on the primitive mesenchymal cells surrounding the cartilaginous anlagen, i.e., proliferating and hypertrophying chondrocytes (13-15). Osteoclast precursors recognize RANKL via RANK expressed on their cell surfaces and differentiate into mononuclear perfusion osteoclasts (POCs) in the presence of M-CSF. RANKL is also involved in mononuclear POC survival and fusion and in mature osteoclast activation (9,14). In contrast, OPG functions as a soluble decoy receptor that competes with RANK to bind RANKL. Consequently, OPG is an effective inhibitor of osteoclast maturation and activation (9,14,16). Recently, Watanabe et al. (15) reported that RANKL, M-CSF, and OPG were expressed in chondrocytes derived from normal human femoral cartilage.

PGE\(_2\) has been detected in TMJ synovial fluid from patients with internal derangement of the joint (17-19). Additionally, plasma levels of PGE\(_2\) reflected general inflammatory activity in such patients (20). PGE\(_2\) is produced when the phospholipids found in cell membranes release arachidonic acid, which is converted by cyclooxygenases (COXs) into prostaglandin H\(_2\), which is subsequently converted into PGE\(_2\) by PGE synthetase. There are two types of COX that regulate this process: COX-1, which is expressed constitutively, and COX-2, which is induced in inflammation (21).

In a previous study that examined the effects of cytokines on osteoclastic differentiation, Watanabe et al. (15) demonstrated that IL-1\(\beta\) suppressed the formation of osteoclast-like cells by increasing OPG production and decreasing M-CSF production in chondrocytes. Their data suggested that OPG induction may be achieved through decreasing M-CSF production in chondrocytes. Their data demonstrated that IL-1\(\beta\) on osteoclastic differentiation, Watanabe et al. (15) which is induced in inflammation (21).

Materials and Methods

Cell culture

Chondrocytes derived from normal human femoral cartilage were obtained from Cell Applications (San Diego, CA, USA). Cells were maintained in Dulbecco’s modified Eagle’s medium/nutrient mixture F-12 (DMEM/F-12; Gibco-BRL, Rockville, MD, USA) supplemented with 10% (v/v) fetal bovine serum (FBS; HyClone Laboratories, Logan, UT, USA), 1% (v/v) insulin-transferrin-selenium-X supplement (Invitrogen, Carlsbad, CA, USA), and 1% (v/v) penicillin-streptomycin solution (Sigma Chemical, St. Louis, MO, USA) at 37°C in a humidified atmosphere of 95% air / 5% CO\(_2\). They were subsequently seeded in 100-mm tissue culture dishes at a density of 5 \(\times\) 10\(^6\) cells/cm\(^2\). After an overnight incubation, the cells were cultured for up to 28 days in DMEM/F-12 containing 10% FBS with or without 50 ng/ml IL-6 and/or 30 ng/ml sIL-6r (R&D Systems, Minneapolis, MN, USA) in the presence or absence of 1 \(\mu\)M NS398. They were examined daily using a light microscope. The concentrations of IL-6 and sIL-6r used in this study were identical to those used by Namba et al. (22), in which the effect of IL-6 and/or sIL-6r on the expression of cartilage matrix proteins in human chondrocytes was examined. The concentration of NS398 used in this study was identical to that used by Ouellet and Percival (23), in which the time-dependency of its COX isoform selectivity was examined.

Real-time PCR

Total RNA was isolated on culture days 1, 3, 5, 7, 14, 21, and/or 28 using an RNaseqy Mini Kit (Qiagen, Valencia, CA, USA). Amounts of RNA were equalized using the human \(\beta\)-actin competitive PCR kit (Takara Bio, Shiga, Japan). The mRNA was used as the template for cDNA synthesis, which was performed using an RNA PCR kit (GeneAmp; Perkin Elmer, Branchburg, NJ, USA). The cDNA mixtures were diluted 5-fold in sterile distilled water and subjected to real-time PCR analysis using SYBR Green I dye (Bio Whittaker Molecular Applications, Rockland, ME, USA). Reaction mixtures (25 \(\mu\)l) contained 2 \(\mu\)l of mRNA, 1 \(\times\) R-PCR buffer, 1.5 mM dNTP mixture, 1 \(\times\) SYBR Green I, 15 mM MgCl\(_2\), 0.25 U Ex Taq (R-PCR version; Takara Bio), and sense and antisense primers (0.2 \(\mu\)M; Table 1). Primers were designed using Primer3 software (Whitehead Institute for Biomedical Research, Cambridge, MA, USA). Assays were performed using a SmartCycler II system (Cepheid, Sunnyvale, CA, USA) and analyzed using the SmartCycler software (ver. 2.0d). Amplification was achieved through 45 cycles of 95°C for 3 s and 60°C for 20 s. Measurements were made at the end of the 60°C annealing step. All real-time PCR reactions were performed in triplicate. Target gene expression levels were normalized to the glyceraldehyde 3-phosphate dehydrogenase (GAPDH) signal.
Enzyme-linked immunosorbent assay (ELISA)

Chondrocytes were incubated in DMEM/F-12 supplemented with 10% (v/v) FBS with or without 50 ng/ml IL-6 and/or 30 ng/ml sIL-6r in the presence or absence of 1 µM NS398 for 1 or 28 days. The culture medium was then replaced with DMEM/F-12 containing 2% (v/v) FBS and 50 ng/ml IL-6 and/or 30 ng/ml sIL-6r, and the cells were cultured for 24 h at 37°C in a humidified atmosphere containing 5% CO₂.

Protein levels of OPG, RANKL, and M-CSF in the culture medium were measured using a commercially available ELISA kit (R&D Systems) according to the manufacturer’s instructions. Amounts of PGE₂ in the culture medium were determined using a commercially available ELISA kit (Assay Designs, Ann Arbor, MI, USA) according to the manufacturer’s instructions. All samples were analyzed in triplicate.

Conditioned medium

Chondrocytes were cultured in DMEM/F-12 supplemented with 10% (v/v) FBS with or without 50 ng/ml IL-6 and/or 30 ng/ml sIL-6r for 28 days. The culture medium was then replaced with DMEM/F-12 containing 2% (v/v) FBS with or without IL-6 and/or sIL-6r, and the cells were incubated for 24 h at 37°C in a humidified atmosphere containing 5% CO₂. Samples of culture medium were then collected and diluted 5-fold in DMEM/F-12 supplemented with 2% (v/v) FBS without IL-6 or sIL-6r and 50 ng/ml soluble RANKL (Wako Pure Chemical, Osaka, Japan) and then used as conditioned medium. The RANKL concentration used was equivalent to that used in a study examining the expression in RAW264.7 cells of enzymes involved in bone resorption (24).

Tartrate-resistant acid phosphatase (TRAP) staining

RAW264.7 cells were plated in 96-well plates at a density of 1.25 × 10⁴ cells/cm² and left overnight to settle. Conditioned medium containing 50 ng/ml soluble RANKL was then applied to the cells for up to 7 days. Cells were then fixed and stained on culture days 3, 5, and 7 using a TRAP staining kit (Takara Bio) according to the manufacturer’s instructions. Numbers of osteoclast-like cells per well were counted. TRAP-positive cells with more than 3 nuclei were considered to be osteoclast-like cells.

Statistical analyses

All experiments were performed in triplicate. Each value represents the mean ± standard deviation (SD). The significance of differences was determined using Bonferroni’s modification of the Student t-test. A P value less than 0.05 was considered significant.

Results

Effects of IL-6 and sIL-6r on the expression of OPG, RANKL, and M-CSF

Chondrocytes were cultured with or without 50 ng/ml IL-6 and/or 30 ng/ml sIL-6r for up to 28 days. OPG, RANKL, and M-CSF mRNA and protein levels were
measured by real-time PCR and ELISA, respectively, on culture days 1, 7, 14, 21, and/or 28 (Fig. 1). In the presence of both IL-6 and sIL-6r, the expression of OPG and RANKL mRNAs increased significantly (1.9- to 2.5-fold and 2.9- to 39.0-fold, respectively) as compared with expression in control cells at the indicated time points (Fig. 1a, c). In contrast, expression of M-CSF mRNA was significantly lower than that in control cells (Fig. 1e). When levels of expression were compared, OPG mRNA had the highest level and RANKL mRNA had the lowest level. Secretion of OPG and RANKL increased significantly (1.5- to 2.4-fold and 1.4- to 1.8-fold, respectively) as compared with that in control cells at the indicated time points (Fig. 1b, d). In contrast, secretion of M-CSF was significantly lower than in control cells (Fig. 1f). When levels of secreted protein were compared, OPG had the highest level and RANKL had the lowest level.

Indirect effects of IL-6 and sIL-6r on TRAP staining of osteoclast-like cells

The indirect effects of IL-6 and sIL-6r on the formation of osteoclast-like cells were examined by staining for TRAP, an osteoclast differentiation marker. RAW264.3 cells were cultured with or without 20% conditioned medium (supplemented with 50 ng/ml soluble RANKL) from untreated chondrocytes or chondrocytes treated for up to 7 days with 50 ng/ml IL-6 and 30 ng/ml sIL-6r. Cells were stained on culture days 3, 5, and 7 and examined using light microscopy. TRAP staining of osteoclast-like cells was weaker after treatment with conditioned medium from chondrocytes treated with IL-6 and sIL-6r than after treatment with conditioned medium from untreated chondrocytes (Fig. 2). Significantly fewer TRAP-positive multinucleated cells were detected on culture day 5 after treatment with conditioned medium from chondrocytes treated with IL-6 and sIL-6r than after treatment with conditioned medium from untreated chondrocytes (Fig. 3).

Fig. 1 Effects of IL-6 and/or sIL-6r on OPG, RANKL, and M-CSF expression. Chondrocytes were cultured with or without 50 ng/ml IL-6 and/or 30 ng/ml sIL-6r for up to 28 days. Expression of OPG, RANKL, and M-CSF mRNA and protein levels was measured by real-time PCR (a, c, e) and ELISA (b, d, f), respectively, on culture days 1, 7, 14, 21, and/or 28. Data represent the mean ± SD of 3 separate experiments. *P < 0.05, **P < 0.01, vs. control.
Indirect effects of IL-6 and sIL-6r on the expression of CA II, MMP-9, and cathepsin K. RAW264.3 cells were cultured with or without 20% conditioned medium (supplemented with 50 ng/ml soluble RANKL) from chondrocytes treated for up to 7 days with 50 ng/ml IL-6 and 30 ng/ml sIL-6r. Expression of CA II, MMP-9, and cathepsin K mRNAs in RAW264.7 cells on culture days 3, 5, and 7 was measured using real-time PCR (Fig. 4). Expression of CA II, MMP-9, and cathepsin K mRNAs at the indicated time points was significantly lower (0.1- to 0.6-fold, 0.2- to 0.4-fold, and 0.1- to 0.2-
fold, respectively) after treatment with conditioned medium from chondrocytes treated with IL-6 and sIL-6r than after treatment with conditioned medium from untreated chondrocytes.

Effects of IL-6, sIL-6r, and NS398 on PGE₂ production

Chondrocytes were cultured with or without 50 ng/ml IL-6 and/or 30 ng/ml sIL-6r in the presence or absence of 1 µM NS398 for up to 28 days. PGE₂ production on culture days 1, 7, 14, 21, and 28 was measured by ELISA (Fig. 5).

PGE₂ production at the indicated time points was significantly higher (2.0- to 6.5-fold) in the presence of both IL-6 and sIL-6r than in their absence (Fig. 5a). NS398 blocked the stimulatory effects of IL-6 and sIL-6r on PGE₂ production on culture day 28 (Fig. 5b). Production of PGE₂ by cells treated with IL-6, sIL-6r, and NS398 was similar to that of untreated control cells.

Effects of IL-6 and/or sIL-6r on COX expression

Chondrocytes were cultured with or without 50 ng/ml IL-6 and/or 30 ng/ml sIL-6r for up to 28 days. Expression of COX-1 and COX-2 mRNAs on culture days 1, 7, 14, 21, and 28 was measured using real-time PCR (Fig. 6).

Expression of COX-2 mRNA at the indicated time points was significantly higher (2.4- to 6.4-fold) in cells treated with IL-6 and sIL-6r than in untreated control cells (Fig. 6b). In contrast, the expression of COX-1 was not affected by treatment with IL-6 and sIL-6r (Fig. 6a).

![Fig. 5 Effects of IL-6, sIL-6r, and NS398 on PGE₂ expression.](image)

(a) Chondrocytes were cultured with or without 50 ng/ml IL-6 and/or 30 ng/ml sIL-6r for up to 28 days. PGE₂ production was measured by ELISA on culture days 1, 7, 14, 21, and 28. (b) Cells were cultured with or without 50 ng/ml IL-6 and 30 ng/ml sIL-6r in the presence or absence of 1 µM NS398. PGE₂ production was measured by ELISA on culture day 28. Data represent the mean ± SD of 3 separate experiments. *P < 0.05, **P < 0.01, vs. control.

![Fig. 6 Effects of IL-6 and/or sIL-6r on COX-1 and COX-2 expression.](image)

Chondrocytes were cultured with or without 50 ng/ml IL-6 and/or 30 ng/ml sIL-6r for up to 28 days. Expression of COX-1 (a) and COX-2 (b) mRNAs was measured using real-time PCR on culture days 1, 7, 14, 21, and 28. Data represent the mean ± SD of 3 separate experiments. **P < 0.01, vs. control.
Effects of IL-6, sIL-6r, and NS398 on the expression of OPG, RANKL, and M-CSF

Chondrocytes were cultured with or without 50 ng/ml IL-6 and/or 30 ng/ml sIL-6r in the presence or absence of 1 µM NS398. Expression of OPG, RANKL, and M-CSF mRNAs on culture day 28 was measured using real-time PCR (Fig. 7). NS398 blocked both the stimulatory effects of IL-6 and sIL-6r on OPG and RANKL mRNA expression (Fig. 7a, b) and the suppressive effects of IL-6 and sIL-6r on M-CSF mRNA expression (Fig. 7c). OPG, RANKL, and M-CSF mRNA expression in cells treated with IL-6, sIL-6r, and NS398 was similar to that in control cells.

Discussion

This study was performed to clarify the effects of IL-6, sIL-6r, and NS398, a specific inhibitor of COX-2 (23), on the expression of OPG, RANKL, and M-CSF in human chondrocytes and the indirect effects of IL-6 and sIL-6r on the generation of osteoclast-like cells from RAW264.7 cells.

The chondrocytes used in this study showed strong expression of type II collagen and aggrecan, a typical phenotype of proliferating, hypertrophic chondrocytes, but expression of type X collagen, a marker of hypertrophic chondrocytes, was very low (data not shown). Thus, the chondrocytes used in this study showed only some of the characteristics of proliferating chondrocytes. In designing these experiments, it was necessary to determine an appropriate length of time for culture. In many previous studies of the expression of OPG, RANKL, and M-CSF in chondrocytes, the culture periods were brief (25-29). However, because TMJ osteoarthrosis is chronically progressive, the expression of mRNA and protein levels in chondrocytes was examined over a much longer period of time, 28 days.

TMJ osteoarthrosis results from an imbalance between anabolic and catabolic processes that are predominantly controlled by chondrocytes (30,31). Cytokines released at sites of inflammation and infection can impair the normal turnover of bone and cartilage, resulting in their pathological destruction or accumulation (32). Additionally, concentrations of inflammatory cytokines and mediators, such as IL-1, IL-6, and PGE2, are increased in the synovial fluid of patients with TMJ osteoarthrosis (3,33). Recently, Namba et al. (22) reported that IL-6 and sIL-6r suppress differentiation of chondrocytes and induce expression of cartilage matrix proteins. On the other hand, Watanabe et al. (15) reported that IL-1β suppressed the formation of osteoclasts by increasing OPGL production via an autocrine mechanism involving the production of celecoxib-related prostaglandins, primarily PGE2, by chondrocytes. Thus, the present study focused on osteoclastic differentiation mediated by RANK/RANKL/OPG, through which chondrocytes communicate with osteoclast precursors. This study showed that the expression of OPG and RANKL in chondrocytes increased significantly in cells cultured with IL-6 and sIL-6r, whereas that of M-CSF decreased. Additionally, it was shown that OPG mRNA expression and protein secretion were significantly higher than RANKL mRNA expression and protein secretion (Fig. 1). In addition, IL-6 and sIL-6r indirectly suppressed osteoclastic differentiation through the function of chondrocytes (Figs. 2 and 3). Palmqvist et al. (34) reported that IL-6 and sIL-6r up-regulated OPG and RANKL in

![Fig. 7 Effects of IL-6, sIL-6r, and/or NS398 on the expression of OPG, RANKL, and M-CSF.](image)

Chondrocytes were cultured with or without 50 ng/ml IL-6 and/or 30 ng/ml sIL-6r in the presence or absence of 1 µM NS398. Expression of OPG (a), RANKL (b), and M-CSF (c) mRNAs was measured using real-time PCR on culture day 28. Data represent the mean ± SD of 3 separate experiments. *P < 0.05, **P < 0.01, vs. control.
neonatal mouse calvarial bones. Additionally, M-CSF is known to be an indispensable factor for the differentiation of osteoclast precursors into mononuclear POCs under the control of the RANK/RANKL/OPG system (9). Thus, the results of the present study suggest that IL-6 and sIL-6r suppress osteoclastic differentiation by increasing OPG production and decreasing M-CSF production, respectively, in chondrocytes.

Mature osteoclasts secrete proteinases (24) and release hydrogen ions (35). The proteinases cathepsin K and MMP-9 are secreted from the ruffled borders of osteoclasts to dissolve the organic components of bone. Hydrogen ions are generated from CO2 and H2O through the action of CA II (24) and pumped by H+-ATPases in osteoclasts into the extracellular space, where they dissolve inorganic bone constituents (35). In this study, the expression of CA II, MMP-9, and cathepsin K in RAW264.7 cells decreased significantly after treatment with conditioned medium from chondrocytes treated with IL-6 and sIL-6r as compared with that after treatment with conditioned medium from untreated control chondrocytes (Fig. 4). These results suggest that IL-6 and sIL-6r indirectly suppress the function of mature osteoclasts by reducing the expression of bone resorption-related enzymes through the function of chondrocytes.

PGE2 is a naturally occurring inflammatory mediator. Watanabe et al. (36) reported that human chondrocytes express PG receptors, including the EP1, EP2, and EP4 receptors, and that IL-1β stimulated expression of EP4 receptor via an autocrine mechanism involving PGE2 production. The present study showed that IL-6 and sIL-6r stimulated PGE2 production in human chondrocytes, a response that was blocked by NS398 (Fig. 5). Additionally, IL-6 and sIL-6r significantly increased the expression of COX-2, but not COX-1 (Fig. 6). These results suggest that IL-6 and sIL-6r induce PGE2 production in chondrocytes by increasing COX-2 expression. To confirm the role of PGE2 in regulating the expression of OPG, RANKL, and M-CSF, the effects of IL-6, sIL-6r, and NS398 on chondrocytes were examined. NS398 blocked the stimulatory effects of IL-6 and sIL-6r on the chondrocytic expression of OPG, RANKL, and M-CSF, which suggests that IL-6 and sIL-6r modulate the expression of OPG, RANKL, and M-CSF via an autocrine mechanism involving the induction of PGE2 production in chondrocytes.

In bone, IL-6 stimulates osteoclastic differentiation and osteoclast activity in association with sIL-6r (34). However, IL-6 exhibits quite different effects in cartilage. Shingu et al. (37) reported that IL-6 promoted the production of tissue inhibitor of metalloproteinases (TIMPs), but not MMPs, in cartilage. Namba et al. (22) reported that IL-6 and sIL-6r induce repair of artrodial cartilage by increasing the expression of cartilage matrix proteins, bone morphogenetic protein (BMP)-7, and BMP-7 receptors in chondrocytes. These previous findings and those of the present study indicate that IL-6 and sIL-6r may protect cartilage and that their action in TMJ osteoarthritis differs between bone and cartilage.

In conclusion, the present findings suggest that IL-6 and sIL-6r suppress both (1) differentiation of osteoclast precursors into osteoclasts by increasing OPG expression and decreasing M-CSF expression via an autocrine mechanism involving the induction of PGE2 production in chondrocytes and (2) the function of mature osteoclasts by decreasing their expression of CA II, MMP-9, and cathepsin K through the involvement of chondrocytes.

Acknowledgments
The author is grateful to Prof. Hideo Matsumura (Dept. of Fixed Prosthodontics), Prof. Masao Maeno (Dept. of Oral Health Sciences), and Prof. Naoto Suzuki (Dept. of Biochemistry) for their valuable guidance and technical expertise, and to Assist. Prof. Yukiko Aida (Dept. of Fixed Prosthodontics) for her appropriate assistance, at Nihon University School of Dentistry.

This study was supported by Special Research Grants for the Development of Distinctive Education from the Promotion and Mutual Aid Corporation for Private Schools of Japan (2008, 2009, 2010).

References
interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis. J Clin Invest 93, 2114-2119.